MicroPort Endovascular Medtech(00853.HK) announced the performance of its subsidiary Shanghai MicroPort Endovascular Medtech(group)co.,ltd. for the first nine months, achieving revenue of 0.97 billion RMB. This marks a 9.1% year-on-year increase. Net profit attributable to shareholders was 0.553 billion yuan, an increase of 42.5%.
微創醫療(00853.HK)附屬心脈醫療科技首九個月賺5.53億人民幣 增長42.5%
Microport (00853.HK) subsidiary shanghai microport endovascular medtech(group)co.,ltd. earned 0.553 billion RMB in the first nine months, a 42.5% increase.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated